Evidence map›Paper›PMID 39771501›Full record

ReviewPharmaceutics2024

Effect of Lipid Nanoparticle Physico-Chemical Properties and Composition on Their Interaction with the Immune System.

Laura Catenacci, Rachele Rossi, Francesca Sechi, Daniela Buonocore, Milena Sorrenti, Sara Perteghella, Marco Peviani, Maria Cristina Bonferoni

Erratum issuedAbstract readReview
In one paragraph

Review in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Decoding Undesirable Inflammatory Responses of Nucleic Acid-Delivering Lipid Nanoparticles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Efficiency and safety of five different agents forFrontiers in molecular biosciences · 2026
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Laura CatenacciDepartment of Drug Sciences, University of Pavia, 27100 Pavia, Italy.ORCID 0000-0001-6791-3785
Rachele RossiDepartment of Drug Sciences, University of Pavia, 27100 Pavia, Italy.
Francesca SechiDepartment of Drug Sciences, University of Pavia, 27100 Pavia, Italy.
Daniela BuonocoreDepartment of Biology and Biotechnology "L. Spallanzani", University of Pavia, 27100 Pavia, Italy.
Milena SorrentiDepartment of Drug Sciences, University of Pavia, 27100 Pavia, Italy.ORCID 0000-0001-8249-5761
Sara PerteghellaDepartment of Drug Sciences, University of Pavia, 27100 Pavia, Italy.ORCID 0000-0003-1128-7636
Marco PevianiDepartment of Biology and Biotechnology "L. Spallanzani", University of Pavia, 27100 Pavia, Italy.ORCID 0000-0002-0576-6166
Maria Cristina BonferoniDepartment of Drug Sciences, University of Pavia, 27100 Pavia, Italy.ORCID 0000-0002-1194-9372

Funding

European Union NextGeneration EU PNRR M4C2-investment1.4-CN00000041
6 · The paper itself

Abstract

Lipid nanoparticles (LNPs) have shown promise as a delivery system for nucleic acid-based therapeutics, including DNA, siRNA, and mRNA vaccines. The immune system plays a critical role in the response to these nanocarriers, with innate immune cells initiating an early response and adaptive immune cells mediating a more specific reaction, sometimes leading to potential adverse effects. Recent studies have shown that the innate immune response to LNPs is mediated by Toll-like receptors (TLRs) and other pattern recognition receptors (PRRs), which recognize the lipid components of the nanoparticles. This recognition can trigger the activation of inflammatory pathways and the production of cytokines and chemokines, leading to potential adverse effects such as fever, inflammation, and pain at the injection site. On the other hand, the adaptive immune response to LNPs appears to be primarily directed against the protein encoded by the mRNA cargo, with little evidence of an ongoing adaptive immune response to the components of the LNP itself. Understanding the relationship between LNPs and the immune system is critical for the development of safe and effective nucleic acid-based delivery systems. In fact, targeting the immune system is essential to develop effective vaccines, as well as therapies against cancer or infections. There is a lack of research in the literature that has systematically studied the factors that influence the interaction between LNPs and the immune system and further research is needed to better elucidate the mechanisms underlying the immune response to LNPs. In this review, we discuss LNPs' composition, physico-chemical properties, such as size, shape, and surface charge, and the protein corona formation which can affect the reactivity of the immune system, thus providing a guide for the research on new formulations that could gain a favorable efficacy/safety profile.

Indexed as

helper lipidsimmune responseionizable cationic lipidslipid nanoparticlesphysico-chemical propertiesprotein corona

Identifiers

PMID39771501
PMCPMC11728546

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.